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MEDIUM TERKONDISI DARIPADA SEL INDUK MESENKIMA YANG 
DIPENCIL DARIPADA SUMSUM TULANG UNTUK PENGEMBANGAN 
SEL INDUK JANTUNG SECARA EX VIVO 
 
ABSTRAK 
Sel induk mesenkima (MSC) daripada sumsum tulang merembes faktor-
faktor parakrin yang mampu merangsang pengaktifan sel induk endogen jantung 
(CSC) dan memperbaiki kefungsian jantung. Faktor-faktor ini boleh dijana melalui 
pelaziman secara in vitro. Tesis ini bertujuan untuk mengoptimumkan kondisi 
pertumbuhan MSC dan perumusan medium yang sesuai untuk menjana medium 
terlazim (CdM) yang mempunyai ciri-ciri “cytoprotective” terhadap CSC.  MSC 
dipencilkan daripada tibia dan femura mencit (C57BL/6N) yang berusia 3-5 
minggu  secara pembilasan sumsum tulang atau dengan menghancurkan tulang 
berkenaan dan dicirikan menggunakan sitometri aliran. Tempoh pre-pelaziman, 
dan kepadatan sel sebelum memulakan pelaziman (Fasa I), perumusan media, 
oksigen, tempoh pelaziman, kesan pengumpulan berulang, dan kepekatan 
pengolahan (Fasa II) dinilai dan dioptimum berdasarkan kesan CdM yang dijana 
terhadap pertumbuhan CSC secara in vitro. Seterusnya, CdM yang telah 
dioptimumkan itu diuji terhadap kadar migrasi CSC. CdM dipekatkan sebanyak 8 
kali kepekatan (Fasa III) dan diuji terhadap pertumbuhan CSC, dibandingkan 
dengan CdM yang tidak dipekatkan. Data dianalisa menggunakan Analisis varians 
(ANOVA) dan Ujian-T. Kepadatan sel yang optimum ketika Fasa I adalah 20, 000 
sel/cm2  dan CdM yang dijana menggunakan  kepadatan sel yang rendah tidak 
menunjukkan kemerosotan yang ketara terhadap pertumbuhan CSC (p>0.05). 
xiii 
 
Tempoh pelaziman yang panjang (48- dan 96-jam) menyusutkan pertumbuhan  
CSC kepada 45.7% dan 53.8%, masing-masing di bawah keadaan tanpa serum. 
Kesan ini diterbalikkan dengan penambahan  10% B27. Gabungan masa pelaziman 
selama 24 jam dengan penambahan glukosa pada kepekatan tinggi (25 mM) di 
dalam DMEM menghasilkan CdM yang menawarkan kesan “cytoprotective” yang 
ketara kepada CSC (p<0.05). Penambahan asid askorbik tidak menunjukkan 
sebarang perubahan ketara terhadap pertumbuhan CSC. MSC yang dilazimkan 
dalam keadaan hipoksia juga tidak menghasilkan CdM dengan ciri-ciri 
“cytoprotective” yang  lebih baik berbanding MSC yang dilazimkan dalam keadaan 
normoksia. Tambahan pula, kaedah pengumpulan berulang tanpa mengira masa 
pelaziman, menunjukkan pengurangan terhadap pertumbuhan CSC yang signifikan 
berbanding CdM yang dikumpul pada pengumpulan pertama, kadar protein di 
dalam CdM juga berkolerasi kuat dengan pertumbuhan CSC (R2=0.855). Tesis ini 
menunjukkan bahawa pengoptimuman berpandu mampu menghasilkan CdM 
daripada MSC daripada sumsum tulang yang mampu merangsang pertumbuhan 
CSC. Kaedah ini berpotensi diterjemahkan untuk pengeluaran  CdM  daripada  
MSC yang dipencilkan daripada manusia secara seragam pada skala yang besar 
untuk penggunaan terapi secara klinikal.   
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CONDITIONED MEDIUM FROM BONE MARROW-DERIVED 
MESENCHYMAL STEM CELLS FOR EX VIVO EXPANSION OF 
CARDIAC STEM CELLS 
 
ABSTRACT 
Bone marrow-derived mesenchymal stem cells (MSCs) have been shown to 
secrete paracrine factors which can stimulate activation of endogenous cardiac stem 
cells (CSCs) and ameliorate infarcted heart function. These factors can be 
harvested through conditioning of MSCs in vitro. This thesis aimed to optimise 
MSC growth conditions and medium formulation for generating conditioned 
medium (CdM) with CSC-cytoprotective properties. Murine MSCs were isolated 
from tibia and femur bones of 3-5 weeks old C57BL6/N mice using flushed 
marrow or crushed bone and was characterised by flow cytometry. Pre-
conditioning time and seeding density before initiation (Phase I), medium 
formulation, oxygen, conditioning time, effects of repeated harvesting, and 
treatment concentration (Phase II) were assessed and optimised based on the effects 
of the produced CdM on CSCs survival in vitro. Then, the optimized CdM were 
tested on CSC migration. To reduce metabolic waste, CdM were concentrated 8 
times (Phase III) and tested on CSC survival, and compared to the crude CdM. All 
data were analysed using ANOVA and t-test. Optimal MSC seeding density during 
phase I was 20,000 cells /cm2 and no significant deterioration in CSC survival with 
CdM generated from MSCs at lower density (p>0.05). Long MSC preconditioning 
time (48 and 96 h) decreased CSC survival to 45.7% and 53.8%, respectively under 
serum starved conditions. This effect could be reversed by adding 10% B27. 
Combination of 24 h pre-conditioning time with high glucose supplemented (25 
xv 
 
mM) DMEM produced CdM that offered significantly greatest cryoprotective 
effects on CSCs (p<0.05). No change in CSC survival when ascorbic acid was 
supplemented in the media. Similarly, hypoxic MSCs did not produce CdM with 
cytoprotective effect superior to that of normoxic MSCs. Furthermore, repeated 
harvesting of CdM, regardless of the conditioning time, shows reduced CSC 
survival compared to CdM from the first harvest, and also the protein level in CdM 
concentrates correlated with CSC survival. This thesis shows guided optimisation 
could produce CSC-stimulating CdM from bone marrow-derived MSCs, and such 
method can be translated onto standardisation of CdM production from human 
MSCs at a larger scale for clinical therapy. 
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1.0 INTRODUCTION 
1.1  Cardiovascular Diseases 
Non-communicable disease (NCD) is the most major cause of mortality and 
morbidity around the globe. According to World Health Organisation (2014), an 
estimation of 38 million of deaths had been reported due to cardiovascular disease 
(CVD), cancer and chronic respiratory disease [1]. Of those, CVD alone had led to 
about 17.5 million deaths worldwide (2012) [2] and the death rate is estimated to 
hike to approximately 22.2 million by 2030 [1]. Similarly in Malaysia, CVD 
remains the top cause of mortality in government hospitals and was accounted for 
20-25% of all reported deaths from 2011 to 2014 [3]. Most of the heart failure 
patients possess a disabled heart that fails to maintain adequate cardiac output and 
normal body circulation, and the disorder is commonly associated with prior 
coronary artery disease and myocardial infarction. 
1.2  Heart Failure: Definition, Pathophysiology and Common 
Therapy 
Myocardial infarction (MI), a progressive disorder involving cardiac cell necrosis 
due to prolonged ischaemia, is the most common cause of heart failure. MI, as a 
result of rupture of atherosclerotic plaque and thrombosis manifested following 
blocked blood flow to the myocardium where the vessel serves and leads to 
substantial loss of functional cardiac myocytes. Series of subsequent cellular and 
molecular changes in response to ischaemia trigger scar formation and disrupt 
cardiac contractility. These deleterious events prompt progressive myocardial 
remodelling and ultimately render the heart to fail. In order to prevent detrimental 
remodelling and to restore heart function, the fibrotic scar needs to be replaced and 
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reconstituted with viable and functional myocytes. However, with the existing 
therapies, especially the pharmacological-based intervention, could only minimize 
the symptoms but is unable to reverse remodelling. To date, the only curative 
treatment option for terminal heart failure is via heart transplantation [4],  but the 
treatment is limited by the complexity of the procedure [5, 6], risk of immune 
rejection, inconsistent outcome after long-term follow-up [7, 8] and limited number 
of organ donors [9, 10]. Implanted ventricular assist device (VAD) may be an 
option to facilitate myocardial performance but such intervention often couples 
with risks of device failure and infections [11]. Hence, stem cells, the guardian of 
cellular homeostasis, have emerged as one of the possible alternatives to address 
the drawbacks of these current therapies.  
1.3  The Role of Stem Cells in Cardiac Regeneration 
Stem cells are unspecialized, self-renewing and proliferative cells which are able to 
differentiate into multiple specialised cells. Many different types of stem cells have 
been identified based on their origin (embryonic or adult tissue) or the 
differentiation potency. The differentiation potency, namely totipotency, 
pluripotency and multipotency, determines stem cell plasticity to acquire the 
phenotypes of specialised cells. Totipotent stem cells have the ability to 
differentiate into all embryonic and extra-embryonic cells. These stem cells have 
the potential to construct the whole body of an organism. Whereas, pluripotent 
stem cells such as embryonic stem cells, can differentiate into all cells in the three 
germ layers namely the ectoderm, endoderm and mesoderm. Lineage committed 
stem cells with restricted differentiation potential are multipotent, of which the 
stem cells are capable of differentiating into cells that are closely related to their 
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tissues and organs. Most of the adult tissue-resident stem cells are multipotent and 
the typical example is the mesenchymal stem cells.  
1.3.1  Embryonic Stem Cells 
Embryonic stem cells (ESCs) are pluripotent stem cells which are derived from the 
inner cell mass of blastocyst. Because of their great proliferation and differentiation 
potential, generation of cardiomyocytes from embryonic stem cells in large number 
is possible hence, making them a good source of cells to facilitate myocardial 
repair following infarction [12]. Nonetheless, transplantation of mixed ESC-
derived myocytes and non-myocytes cells in SCID mice showed transient 
improvements in cardiac function after 12 weeks [13]. Furthermore, issues related 
to ethics, allogeneic rejection and risks of teratoma formation remain unresolved 
[14, 15], thus precluding the use of ESCs in human application.  
1.3.2  Adult Stem Cells 
Adult stem cells (ASCs) are mostly multipotent stem cells, which can be found in 
most adult tissues including the skeletal muscles [16], bone marrow [17], heart 
[18], kidney [19], and lungs [20]. Most of the adult stem cells are multipotent stem 
cells, and the typical example of the multipotent stem cells includes the skeletal 
myoblast, endogenous cardiac stem cells and also bone marrow derived stem cells.  
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1.3.2(a)  Skeletal Myoblast 
Skeletal myoblast are undifferentiated satellite cells situated in skeletal muscles. 
The use of skeletal myoblast was proven as safe and feasible for cardiac therapy 
following ischemic injury [21-24]. However, phase 2 randomized, placebo-
controlled Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) 
trial failed to observe an improvement in cardiac function after transplanting 
skeletal myoblast into ischemic heart, and possessed significant  risk of ventricular 
arrhythmias [25]. Despite the differentiation capacity of the skeletal myoblast to 
form multinucleated myotubes  in the heart as reported in studies involving several 
animal heart infarct model  such as in mice [26], rats [27], and also pigs [28], the 
lack of expression of adhesion molecules such as N-cadherin and connexin-43, the 
important components for gap junction formation and synchronisation with host 
myocardium, was found to be responsible for the observed ventricular arrythmias 
[29, 30]. 
1.3.2(b)  Endogenous Cardiac Stem Cells 
Heart previously believed to be a terminally differentiated organ with almost no 
intrinsic regenerative potential to circumvent the impact of myocardial infarction.  
Recently, the dogma was challenged following the discovery of a small population 
of endogenous cardiac stem cells. Beltrami et al (2003) demonstrated that Linneg C-
kitpos cells isolated from the adult rat myocardium have the ability to self-renew, 
form clones and capable of differentiating into cardiac lineage [18]. These cells 
have shown to regenerate the infarcted myocardium [18, 31, 32]. Despite the 
identification of several other types of endogenous cardiac stem cells such as Sca-1 
[33, 34], Islet-1 [35, 36], ABCG2 [37, 38] and cardiospheres [39, 40], c-kit cardiac 
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stem cells remains the most promising myocyte-committing cells and had been 
tested in phase 1 SCIPIO trial [41]. The discovery of cardiac stem cells offer hope 
for regenerating injured myocardium. However, these stem cells are present in low 
number, and extensive expansion technique is required to obtain relevant cell 
number. In order to maintain the stemness and the functionality of the isolated 
CSCs during expansion, the culture medium for the maintenance of the cells in 
vitro requires the supplementation of cocktails of growth factors [42].  
1.3.2(c)  Bone Marrow-derived Stem Cells 
Bone marrow-derived stem cells are heterogeneous stem cells that reside in the 
sinusoidal periphery of bones [43]. They comprised of mainly the hematopoietic 
stem cells, proliferative mononuclear cells and mesenchymal stem cells with multi-
lineage differentiation potential. Bone marrow-derived stem cells were also used as 
a cell candidate for treating infarcted heart [44-46], lung [47], kidney [48], renal 
[49], and also damaged skin [50]. Autologous transplantation of bone marrow-
derived stem cells improved angiogenesis and cardiac function [51], and injection 
of lineage depleted c-kit expressing bone marrow-derived stem cells  was found to 
regenerate almost 68% of the infarcted region at only 9 days post-injection [52]. 
However, long-term benefit was not sustained [53-57]. This hypothesis was also 
confirmed in the BOOST trial, which reported that intracoronary injection of 
autologous bone marrow-derived stem cells enhanced the level of left ventricular 
ejection fraction (LVEF) within six months after administration [58], but not after 
18 months [59] or 5 years [60] follow-up.  
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1.4  The Role of Mesenchymal Stem Cells in Myocardial Infarction 
Mesenchymal stem cells (MSCs) are one of the non-hematopoeitic stem cells that 
form the hematopoietic niche which supports the hematopoietic stem cells turnover 
inside the bone marrow [61, 62]. The International Society for Cellular Therapy 
(ISCT) proposed standardised criteria to define MSCs which include, (a) adhesive 
to plastic in standard culture condition, (b) positive expression of stem cell markers 
such as CD105, CD73, CD90, and negative expression of CD45, CD34, CD11b, 
CD19 and HLA-DR, and (c) possess differentiation capacity to form adipocytes, 
osteocytes and chondrocytes [63]. They have also been shown to trans-differentiate 
into cells which are developmentally unrelated to their origin such as nerve cells 
and heart muscle cells [44, 64, 65]. MSCs are easily isolated from various adult 
tissues and the common sources are from bone marrow, adipose tissues and cord 
blood. [66]. Previous evidences have shown that MSCs engrafted, and retained for 
a few weeks; and regenerated infarcted pig myocardium [45, 46, 67]. Allogeneic 
transplantation of MSCs via intra-myocardial route showed progressive reduction 
of infarct scar size after 6 months, with persistent improved  LVEF after 12 months 
[68].  
MSCs are known to have immune-regulatory properties. They interact with the 
cellular components of both the innate and adaptive immune cells, affecting the 
immune response [69]. MSCs secrete molecules and soluble factors such as tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor 
(TGF-β), all of which act to suppress the action of the inflammatory cells, thus 
evading the immune response [70]. These properties make allogeneic 
transplantation of immunologically naïve MSCs a great alternative for regenerative 
therapy [71]. In POSEIDON trial the effects of the injection of allogeneic and 
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autologous MSCs were tested in patients with ischemic cardiomyopathy [72]. This 
study also shows that low dose cell injection at 20 million cells was more efficient 
than high dose injection at 200 million cells in treating patients with chronic left 
ventricular dysfunction, regardless of the source of which the cells were derived 
from, be it allogeneic or autologous. In the most recent clinical trial, the 
PROMETHEUS trial, autologous MSC injection at the infarcted segments showed 
reduced regional scar size and improved left ventricular performance after 18-
months follow-ups [73]. Similar observations were also reported in TAC-HFT trial 
which employed trans-endocardial injection of autologous MSCs in patients with 
heart failures. Significant improvements in infarct scar size reduction and regional 
myocardial function restoration were observed in patients after 12-months. More 
importantly the quality-of-life of these heart failure patients were also improved, 
considerably [74].  
Accumulating evidences suggest that MSC have  the ability to mobilise, engraft 
and  integrate into the host myocardium [46, 67, 75] via gap junctions [45, 76]. 
Noiseux et al. (2006) showed the possibility that MSCs transiently engrafted, fused 
with the cardiomyocytes and trans-differentiated into new and viable 
cardiomyocytes [77]. This finding was parallel with a report which confirmed the 
presence of hybrid cells, as a result of spontaneous cellular fusion between human 
MSCs and neonatal rat ventricular cardiomyocytes [78]. However, the degree of 
cellular fusion was negligible and the improvement in cardiac function was 
transient. On the other hand, the indirect regenerative mechanism of MSCs was 
found whcih involve paracrine secretion that triggers endogenous healing process 
in the infarcted heart without noticeable engraftment [79-82]. 
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1.4.1  The Roles of Mesenchymal Stem Cells in Cardiac Repair 
MSCs have been shown to possess cardioprotective properties. Several in vivo 
investigation have demonstrated that administration of MSCs improved global 
function, reduced scar size, increased angiogenesis within infarct myocardium [83] 
and protected from ischemic/reperfusion injury [84]. These effects can be further 
augmented by overexpressing certain pro-survival genes such as Akt [85] or GSK-
3β [86]. Furthermore, direct contact of MSCs with cardiomyocytes stimulates MSC 
paracrine repair via tunnelling nanotubes [87] in addition to juxtacrine noth-
1/jagged-1 signaling that triggers cardiomyocyte proliferation [88]. However, little 
evidence supports the notion that MSCs contribute to direct new myocyte 
formation via trans-differentiation [89, 90], and the main cardiac regenerative 
mechanism exerted by MSCs is via secretion of paracrine factors [91] and 
exosomes [92].  
1.5  Conditioned Medium as the Alternative Therapy 
Transplantation of allogeneic stem cells often couples with risks of developing 
graft rejection or tumour formation. MSCs are known to secrete an array of 
signalling molecules such as cytokines, growth factors, and extracellular matrix 
(ECM), which regulate its own function, survival and also provide trophic effects 
onto the neighbouring tissues [93, 94]. These paracrine mediators also play a key 
role in stimulating the repair mechanisms in the ischemic region [95, 96]. Previous 
studies also showed that improvement in cardiac function was not associated with 
high retention and engraftment of transplanted stem cells in the injured site, but due 
to its paracrine effects [82, 97, 98]. This also prompts the effort to harvest MSC 
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secretomes in conditioned medium to serve as an alternative, off-the-shelf 
treatment for therapy without the presence of stem cells [99].  
1.6 Mesenchymal Stem Cells-derived Conditioned Medium and its 
 Effects in Cardiac Stem Cells in vitro and in vivo 
MSC-derived conditioned medium had been used in treating heart [79, 80, 100], 
lung [101-103], liver [104, 105], kidney [106, 107], and skin [108-111], primarily 
through its effects on angiogenesis and neovascularization [112-114]. Treatment 
with MSC-derived conditioned medium alone was also found to reduce infarct size, 
increase capillary density, preserve myocardial function [115-117] and limit the 
onset of fibrosis through the inhibition of matrix metallo-protenaise endogenous 
inhibitor (TIMP) [118]. Priming with MSC-conditioned medium activates CSCs 
[119] and transplantation of the treated cells showed improved engraftment, 
survival and migration in ischemic hearts [120]. Accumulating data supported the 
synergistic relationship between MSCs and CSCs in myocardial regeneration and 
co-transplantation of both cells showed greater therapeutic efficacy in vivo [121, 
122]. The fusion of CSCs and MSCs, or termed cardiochimeras, also revealed 
significant attenuation of ventricular and amelioration of infarcted heart functions 
[123]. CSCs are known to be activated by two main growth factors, the insulin-like 
growth factor-1 (IGF-1) and hepatocytes growth factor (HGF). Studies also showed 
that injection of IGF-1 and HGF promotes endogenous myocardial repair [124] via 
activation of cardiac stem cells [125]. Moreover, CSCs can be mobilised with 
VEGF/SDF-1 in mediating myocardial repair in rat [126]. These factors have been 
identified as part of the secretome from bone marrow MSCs [127-130], in addition 
to others cardioprotective factors such as platelet-derived growth factor (PDGF) 
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[131, 132] and stromal-derived factor-1 (SDF-1)[133], as well as IGF-1 [134] and 
VEGF [135]   
1.7 Generation of Mesenchymal Stem Cells -derived Conditioned Medium  
The growth parameters that regulate the MSC physiochemical and spatiotemporal 
activities are accounted for improved MSC secretory functions. The use of 
conditioned medium is however, hampered by the lack of standardised production 
method with high consistency. To date, no standardised protocol has been proposed 
to reproducibly manufacture CdM from MSCs. Hence, optimisation of MSC 
culture is needed to ensure the production of paracrine-factor rich conditioned 
medium from MSC is suitable and effective for the use in therapy.  This includes 
MSC seeding density and incubation time prior to conditioning, duration for 
conditioning, number of repeated CdM harvest, medium formulation (choice of 
medium, serum/serum replacement, ascorbic acid supplementation, glucose 
concentration) for conditioning MSCs, and the need for generating CdM 
concentrates.  
1.7.1  Medium Formulation for Generating Mesenchymal Stem Cell-
 derived Conditioned Medium 
 
1.7.1(a)  Choice of Medium 
There are various basal medium which are commercially available for stem cell 
expansion and maintenance. These media are generally formulated to increase 
survival and proliferation of specific cells, whilst maintaining its regulatory 
function in vitro. Therefore, choosing an optimal culture medium is important to 
produce healthy and viable MSCs, and to preserve its paracrine secretory function. 
Based on previous publications, the most commonly used culture media for 
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maintaining MSCs are Dulbecco’s Modified Eagle Medium (DMEM) [101, 136-
139], DMEM/F12 [109, 128], α-Minimal Eagle Medium (MEM) [79, 106, 140] 
and Iscove’s Modified Dulbecco’s Medium (IMDM) [141-143] (Table 1.1). α-
MEM was found to be the optimal culture medium to maintain the human bone 
marrow derived MSC [144] although DMEM is the most frequently used culture 
medium in preparing MSCs [145]. Knock-Out DMEM or DMEM with F12 
supplementation were found to maintain the typical spindle-like shape cells and 
were shown as the optimal culture medium that preserved MSC growth 
characteristics up to 25 passages with 10% serum [145]. Nonetheless, no consensus 
has been reached to define the optimum medium for generating MSC-derived 
conditioned medium. 
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Table 1.1: Basal medium used in previous studies for generating conditioned medium. 
DMEM DMEM/F12 α-MEM IMDM 
 Attenuates 
ischemic/reperfusion 
injury with addition on 
the onset of the 
reperfusion [136] 
 Enhances skin wound 
healing [109] 
 Enhances skin wound 
healing [111] 
 Protection from hypoxia-
induced damage on 
cardiomyocytes [142] 
 Promotes the 
proliferation and 
migration of corneal 
endothelial cells [139] 
 Improves ventricular 
functions [128] 
 Inhibits cIPTEC  death 
following nephrotoxicity 
and promotes cell 
migration [106] 
 Improves electrical 
coupling of iPS-
cardiomyocytes [141] 
 Attenuates lung 
inflammation following 
LPS-induced lung 
injury [138] 
  Protect cardiomyocytes 
from hypoxic injury and 
improves ventricular 
functions [79] 
 Immunosuppressive 
potential [143] 
 Promotes HUVECs 
migration [137] 
   
 Recovers lung 
regeneration following 
cigarette smoke 
induced damage [101] 
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1.7.1(b)   Glucose  
Glucose is the main energy source required in stem cell expansion which regulates 
the signalling pathways that involved in cell survival and proliferation through the 
production of adenosine triphosphate (ATP) [146]. Two types of glucose which can 
be added manually into the culture medium namely the D-glucose and its 
enantiomers, L-glucose. L-glucose is unstable, while dextrose or D-glucose is the 
naturally occurring glucose. Glucose was found to be indispensable for MSC pre-
conditioning prior to transplantation [147]. High glucose was found neither acutely 
affect proliferation and differentiation [148] nor the production of secreted growth 
factors. Instead, the latter was found to be associated with the presence of stressors 
such as tumour necrosis factor-α (TNF-α) and lipopolysaccharide (LPS), which up-
regulated the production of vascular endothelial growth factors (VEGF), hepatocyte 
growth factor (HGF) and fibroblast growth factor-2 (FGF-2) in MSCs [149]. On 
the contrary, others found that high glucose induces replicative senescence in 
MSCs [150] and inhibits its angiogenic properties in hypoxia-induced tissue injury 
due to increased intracellular superoxide [151].  
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1.7.1(c)  Serum Supplementation 
Serum is essential for ex vivo expansion of stem cells because it contains abundant 
growth mediating factors [152]. Most of the time, MSCs were maintained in 
medium supplemented with animal serum [153]. Different level of serum had also 
been used to grow MSCs for harvesting conditioned medium (Table 1.2). However, 
the presence of animal-derived entities such as prions, ethical issues regarding the 
collection of the serum from animal foetus, the potential of cross-species 
contamination and risk of batch-to-batch variation impedes its application in 
culturing stem cells for clinical transplantation [154]. On the other hand, reduced 
serum concentration was revealed to have an inhibitory effect on MSC proliferation 
and did not preserve the expression of cell surface marker [145]. Although 
chemically defined serum free media are introduced to expand clinically-compliant 
MSCs, most xeno-free media is not cost effective for  large production of MSCs in 
clinical applications [155]. In order to formulate the culture medium for generating 
MSC-derived conditioned medium, reduced supplementation of xeno-serum is 
particularly important, and a balance between MSC growth and its supplementation 
should be achieved without compromising MSC paracrine function. B27 is a 
serum-free supplement for the growth of the hippocampal neurons that was 
developed by the optimisation of over 20-components of the previously published 
supplement namely the B18 [156]. Other than hippocampal neurons [157], B27 
also had been reported to maintain the growth and survival of retinal pigment 
epithelium cells [158] and also skin-derived MSCs [159].  
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Supplementation of ascorbic acid, a potent antioxidant [160, 161] in the MSC 
culture and the benefits were well described inclusively as anti-cancer [162, 163], 
immunosuppressant [164], anti-leukemic [165, 166] and anti-apoptotic [167, 168]. 
The supplementation of ascorbic acid also had been proven to enhance MSC 
proliferation and differentiation potential [169, 170], and improve embryonic stem 
cell cardiomyogenic differentiation potential of [171] and induced pluripotent stem 
cells [172].  
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Table 1.2: The level of serum used to generate conditioned medium reported in previous studies. 
 
Serum free 1% 2% 10% 
 Induction of endothelial 
cells migration and 
proliferation, improved 
circulation to ischemic 
hind limbs [173] 
 Induce angiogenic 
potential of endothelial 
cells [174] 
 Stimulate the increase 
in SDF-1 expression, 
promoting the CSC 
migration, partly by 
SDF-1/CXCR4 binding  
[126] 
 Inhibits cIPTEC  death 
following 
nephrotoxicity and 
promotes cell migration 
[106] 
 Improves neuron 
recovery following 
spinal cord injury [175] 
 Promotes angiogenic 
potential of endothelial 
progenitor cells [112] 
  Reduce the viability of 
cardiac fibroblast, 
decreasing the chance 
of developing cardiac 
fibrosis [118] 
 Promotes HCEC 
expansion, proliferation 
and wound healing 
potential [139] 
   
 Promotes angiogenesis 
by juxtacrine and 
paracrine signaling 
[114] 
   
 Reduced myocardial 
infarct size and 
improved cardiac 
function [176] 
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1.7.2  Growth Conditions for Generating MSC-derived Conditioned  
  Medium 
1.7.2(a)  Oxygen 
Physiological oxygen partial pressure inside the tissues is within the range of 2-9% 
O2 following tissue oxygenation [177, 178]. Most commonly in normal ex vivo 
culture, MSCs were maintained under ambient atmospheric oxygen partial 
pressure, between 20-21% O2, a much higher level than the physiological level. 
HIF-1 complex consists of constitutively expressed HIF-1β and HIF-1α subunits 
which are tightly regulated by oxygen partial pressure. The expression of HIF-1α is 
up-regulated in low oxygen or hypoxic condition [179]. HIF-1α expression in stem 
cells under hypoxia can enhance MSC proliferation, differentiation [180, 181], 
migration [181, 182], skin wound healing [183, 184] and preserve the ability of 
MSCs to secrete growth mediating factors such as pro-angiogenic growth factors 
responsible for vascular regeneration [137, 185, 186]. HIF-1α is also required in 
modulating the transcription activity that involves in cardiac recovery following 
myocardial infarction [187, 188]. Several reports showed that oxygen level affects 
MSC function and alters its paracrine secretion (Table 1.3). Therefore, oxygen 
level is one of the crucial components in deciding the optimal MSC growth and its 
conditioned medium.  
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Table 1.3: The oxygen concentration in generating conditioned medium and the cyto-protective effect it exerts on the various stem 
cells. 
 
21%  2%  < 2% 
 Increases blood flow and 
angiogenesis [189] 
 Stimulates the expression of 
VEGF, IL-6, IL-8, and bFGF 
inducing the increased wound 
healing capacity [108] 
 Calvarial bone regeneration 
[190] 
 Pro-angiogenic, protects 
neurons from apoptosis and 
activates the macrophage 
activity [175] 
  Protection from hypoxic 
induced injury and improves 
ventricular performances (0.5% 
oxygen)[79] 
 Reduces myocardial infarct 
size and improved cardiac 
function [176, 191] 
  Promotes MSCs proliferation 
and represses senescence (<1% 
and 5% oxygen)[192] 
 Protects lung fibroblast from 
cigarette smoke induced injury 
[193] 
  Accelerates skin wound healing 
(1% oxygen)[194] 
 Promotes angiogenesis by 
juxtacrine and paracrine 
signalling [114] 
  Promotes migration of 
endothelial cells (EC) (1% 
oxygen)[195] 
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1.7.2(b)  Incubation Time and Seeding Density 
MSCs cultured at low density had shown to be better than that of high density 
culture [144, 196, 197]. A previous study reported that low seeding density at 200 
cells/ cm2 was favoured as it maintained the growth pattern and kinetics of bone 
marrow stromal cells [198]. The same study suggested that the relationship 
between the cell seeding densities with incubation time exists, as MSCs undergo 
phenotypic change from spindle-like shape into flat shaped cells under long 
incubation time [198].  
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Table 1.4: Different length of incubation time for generating conditioned medium and its function as reported in the previous studies 
 
 
24 hour 48 hour 72 hour 
 Induces neuro-restoration and 
endothelium repair [199] 
 Protects the cardiomyocytes and 
stimulates anti-apoptotic 
potential due to hypoxic injury 
[200] 
 Reduces myocardial infarct size and 
improves cardiac function [176] 
 Increases cardio-protection [142]  Stimulates STAT3 and AKT 
activation which improves CPC 
proliferation and protection from 
hypoxic injury, sustained 
multipotency and improves graft 
success after MI. [120] 
 Enhances skin wound healing [109] 
 Improves angiogenesis and 
increases endothelial cells 
proliferation [113] 
 Enhances wound healing [201]  
 Improves angiogenesis, chemotaxis 
and increased arteriolar density, 
vascularisation index and 
vascularisation flow index in the 
Matrigel plug [114] 
 Exerts pro-migratory effect of 
cardiac appendage stem cells 
(CASCs)[202] 
 
  Attenuates severe limb loss and 
angiogenesis in ischemic hind 
limbs [189] 
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Problem Statement 
Conditioned medium (CdM) could enhance endogenous cardiac stem cell viability 
and functions. However, no standard protocol for generating conditioned medium 
from bone marrow-derived stem cells is available for ex vivo expansion of 
endogenous cardiac stem cells.  
Hypothesis:  
Conditioned medium from bone marrow derived mesenchymal stem cells 
generated under the specific culture parameters can be used to culture and maintain 
cardiac stem cells with preserved stemness and enhanced functions. 
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Objectives 
To generate bone marrow MSC-derived CdM that can enhance cardiac stem cells 
(CSC) survival.   
Specific objectives: 
1. To isolate and to characterise bone marrow-derived mesenchymal stem 
cells from C57BL/6N mice.  
2. To optimise MSC growth conditions prior to initiation of conditioning for 
generating CdM and testing on CSC survival. 
3. To examine the optimal media formulation (choice of basal medium, serum 
concentration/serum replacement, ascorbic acid and glucose concentration) 
and growth conditions (duration for conditioning and oxygen level) for 
generating to generate MSC-CdM and identify the optimum CdM 
concentration for testing its efficacy on CSC survival in vitro. 
4. To generate CdM concentrates and to test its effectiveness on CSC survival.  
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2.0 MATERIALS AND METHOD 
2.1  General Methodologies 
The general methodologies described the medium formulation and reagents used in 
bone marrow-derived mesenchymal stem cells and cardiac stem cell culture and 
maintenance.  All growth media were stored at 4℃  
2.1.1  Standard Growth Medium 
Complete growth medium was prepared using DMEM supplemented with 1x 
pen/strep (Gibco, USA) and 10% FBS (Gibco, USA) and used for MSC expansion 
and maintenance for subsequent experiments. For initial isolation of the mouse 
MSCs, thr growth medium was supplemented 7% horse serum (HS) (Gibco, USA) 
to boost cell proliferation. 
2.1.2  Mouse Endogenous Cardiac Stem Cells (CSCs) Growth Medium 
Cardiac stem cell medium was formulated based on published method (ref). 
Briefly, the medium comprised of two solutions which were then mixed at 1:1 
ratio. Solution 1 was prepared in DMEM/F12 (Gibco, USA) supplemented with 1% 
(v/v) Insulin-Transferin-Selenium (ITS) (Gibco, USA), 1% (v/v) pen/strep, 0.1% 
(v/v) fungizone (Gibco, USA) and 0.1% (v/v) gentamicin (Gibco, USA). Solution 2 
was prepared with Neurobasal medium (Gibco, USA) supplemented with 74 mg/ml 
L-glutamine (Gibco, USA), 2% (v/v) B27 supplement (Gibco, USA) and 1% (v/v) 
N2 supplement (Gibco, USA). The two solutions were then mixed at the ratio of 
45% Solution 1: 45% Solution 2: 10% (v/v) embryonic stem cells-qualified foetal 
bovine serum (ESC-FBS) (Gibco, USA). Epidermal growth factor (20 ng/ml), basic 
fibroblast growth factor (10 mg/ml) and leukemic inhibitory factor (20 ng/ml) were 
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added and the medium was filtered through 0.22-μm filter system and stored in the 
sterile container. 
2.1.3  Incubation Medium 
Incubation medium was Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco, 
USA) supplemented with 5 mg/ml bovine serum albumin (BSA) (Nacalai Tesque, 
Japan), 2 mM ethylene-diamine-tetra-acetic acid (EDTA) (Sigma-Aldrich, USA), 
1x penicillin/streptomycin, 0.1% fungizone and 0.1% (v/v) gentamicin (Gibco, 
USA).  
2.1.4  Flushing Medium  
Cell flushing medium was DPBS supplemented with 1% penicillin/streptomycin 
and 2% (v/v) FBS (Gibco, USA).  
2.1.5  Gelatin  
Endogenous cardiac stem cells were cultured in the vessels coated with 1.5% (v/v) 
gelatin. The preparations need about 0.75 g gelatin from porcine skin (Sigma-
Aldrich, USA) diluted in 50 ml DPBS (Gibco, USA). The mixture was then heated 
in the microwave oven for 30 seconds, cooled and sterile filtered with 0.22-μm 
syringe driven filter before use.  
2.1.6  MSC Differentiation Medium 
StemPRO differentiation medium was prepared by supplementing 1x StemPRO 
Adipogenesis, Osteogenesis or Chondrogenesis Supplement (Gibco, USA), 
respectively, with additional 5 μg/ml gentamicin (Gibco, USA) in each medium. 
All media were protected from  light.  
